关注
Shahrad Rod Rassekh
Shahrad Rod Rassekh
University of British Columbia; BC Childrens Hospital
在 cw.bc.ca 的电子邮件经过验证
标题
引用次数
引用次数
年份
Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children
H Visscher, CJD Ross, SR Rassekh, A Barhdadi, MP Dubé, H Al-Saloos, ...
Journal of clinical oncology 30 (13), 1422-1428, 2012
4422012
Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston …
PR Brock, KR Knight, DR Freyer, KCM Campbell, PS Steyger, BW Blakley, ...
Journal of Clinical Oncology 30 (19), 2408-2417, 2012
4212012
Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy
CJD Ross, H Katzov-Eckert, MP Dubé, B Brooks, SR Rassekh, ...
Nature genetics 41 (12), 1345-1349, 2009
3642009
A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer
F Aminkeng, AP Bhavsar, H Visscher, SR Rassekh, Y Li, JW Lee, ...
Nature genetics 47 (9), 1079-1084, 2015
2642015
Recommendations for genetic testing to reduce the incidence of anthracycline‐induced cardiotoxicity
F Aminkeng, CJD Ross, SR Rassekh, S Hwang, MJ Rieder, AP Bhavsar, ...
British journal of clinical pharmacology 82 (3), 683-695, 2016
2232016
Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline‐induced cardiotoxicity in children
H Visscher, CJD Ross, SR Rassekh, GSS Sandor, HN Caron, ...
Pediatric blood & cancer 60 (8), 1375-1381, 2013
2042013
Replication of TPMT and ABCC3 Genetic Variants Highly Associated With Cisplatin‐Induced Hearing Loss in Children
K Pussegoda, CJ Ross, H Visscher, M Yazdanpanah, B Brooks, ...
Clinical Pharmacology & Therapeutics 94 (2), 243-251, 2013
1412013
Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers
J Laskin, S Jones, S Aparicio, S Chia, C Ch'ng, R Deyell, P Eirew, A Fok, ...
Molecular Case Studies 1 (1), a000570, 2015
1252015
Genetic Variants in SLC22A17 and SLC22A7 are Associated With Anthracycline-Induced Cardiotoxicity in Children
H Visscher, SR Rassekh, GS Sandor, HN Caron, EC Van Dalen, ...
Pharmacogenomics 16 (10), 1065-1076, 2015
1172015
Personalizing the treatment of pediatric medulloblastoma: polo-like kinase 1 as a molecular target in high-risk children
J Triscott, C Lee, C Foster, B Manoranjan, MR Pambid, R Berns, ...
Cancer research 73 (22), 6734-6744, 2013
1102013
Evaluating the quantity, quality and size distribution of cell-free DNA by multiplex droplet digital PCR
M Alcaide, M Cheung, J Hillman, SR Rassekh, RJ Deyell, G Batist, ...
Scientific reports 10 (1), 12564, 2020
882020
Long-term outcomes and complications in pediatric Ewing sarcoma
SN Hamilton, R Carlson, H Hasan, SR Rassekh, K Goddard
American journal of clinical oncology 40 (4), 423-428, 2017
802017
Outcome of infants and young children with newly diagnosed ependymoma treated on the “Head Start” III prospective clinical trial
R Venkatramani, L Ji, J Lasky, K Haley, A Judkins, S Zhou, R Sposto, ...
Journal of neuro-oncology 113, 285-291, 2013
792013
Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients
M Science, PD Robinson, T MacDonald, SR Rassekh, LL Dupuis, L Sung
Pediatric Blood & Cancer 61 (3), 393-400, 2014
712014
Pharmacogenomics of vincristine‐induced peripheral neuropathy implicates pharmacokinetic and inherited neuropathy genes
GEB Wright, U Amstutz, BI Drögemöller, J Shih, SR Rassekh, MR Hayden, ...
Clinical Pharmacology & Therapeutics 105 (2), 402-410, 2019
692019
Antidepressant use among survivors of childhood, adolescent and young adult cancer: a report of the Childhood, Adolescent and Young Adult Cancer Survivor (CAYACS) Research Program
RJ Deyell, M Lorenzi, S Ma, SR Rassekh, JP Collet, JJ Spinelli, ...
Pediatric blood & cancer 60 (5), 816-822, 2013
632013
Clinical practice recommendations for the management and prevention of cisplatin-induced hearing loss using pharmacogenetic markers
JW Lee, K Pussegoda, SR Rassekh, JG Monzon, G Liu, S Hwang, ...
Therapeutic drug monitoring 38 (4), 423-431, 2016
602016
Comparison of hypersensitivity rates to intravenous and intramuscular PEG‐asparaginase in children with acute lymphoblastic leukemia: a meta‐analysis and systematic review
H Hasan, OM Shaikh, SR Rassekh, AF Howard, K Goddard
Pediatric blood & cancer 64 (1), 81-88, 2017
592017
Childhood, adolescent, and young adult cancer survivors research program of British Columbia: objectives, study design, and cohort characteristics
ML McBride, PC Rogers, SB Sheps, V Glickman, AM Broemeling, ...
Pediatric blood & cancer 55 (2), 324-330, 2010
592010
VKORC1 and CYP2C9 genotypes are predictors of warfarin‐related outcomes in children
K Shaw, U Amstutz, C Hildebrand, SR Rassekh, M Hosking, K Neville, ...
Pediatric blood & cancer 61 (6), 1055-1062, 2014
522014
系统目前无法执行此操作,请稍后再试。
文章 1–20